Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Prostate Cancer Diagnostics Market by Type (Tumor Biomarker Tests, Imaging, Biopsy, Other), By Application (age < 55, age 55-75, age > 75) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Prostate Cancer Diagnostics Market by Type (Tumor Biomarker Tests, Imaging, Biopsy, Other), By Application (age < 55, age 55-75, age > 75) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130948 3300 Pharma & Healthcare 377 242 Pages 4.6 (42)

Market Overview:

The global prostate cancer diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of prostate cancer, technological advancements in prostate cancer diagnostics, and increasing demand for early diagnosis and treatment of prostate cancer. Based on type, the global prostate cancer diagnostics market is segmented into tumor biomarker tests, imaging, biopsy, and other tests. The tumor biomarker tests segment is expected to account for the largest share of the global market in 2018. This can be attributed to the growing use of tumor biomarkers for early detection and diagnosis of prostate cancer. Based on application, the global market is divided into three segments: age < 55 years old; age 55-75 years old; and age > 75 years old.

Global Prostate Cancer Diagnostics Industry Outlook

Product Definition:

Prostate cancer diagnostics is the process of detecting and diagnosing prostate cancer. It involves a number of tests and procedures, including a digital rectal examination (DRE), a blood test for prostate-specific antigen (PSA), an ultrasound exam, and a biopsy. Prostate cancer diagnostics is important because it allows doctors to identify and treat prostate cancer at an early stage, when the chances for successful treatment are greatest.

Tumor Biomarker Tests:

Tumor biomarker tests are laboratory tests that measure the presence of certain substances in tumors, which are released by the body as a response to injury or trauma. These substances can act as tumor markers orbiomarkers and help diagnose various types of cancers. Some commonly used biomarkers include CA-125 (caustic soda test), PSA (prostate specific antigen), and HbA1c (glycosylated hemoglobin).


Imaging techniques are used for the detection of prostate cancer. Imaging techniques include ultrasound, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, and X-ray. The choice of imaging technique depends on several factors such as patient age, presence or absence of symptoms at the time of diagnosis, physician preference and experience with a particular imaging technique among others.

Application Insights:

The age group of 55 to 75 years held the largest share of over 50.0% in 2017. This is due to the increasing prevalence of prostate cancer and rising demand for more effective treatment options across this demographic. For instance, according to data published by the U.S National Cancer Institute, around 1 in 6 men aged 65 or above were diagnosed with prostate cancer in 2016 compared with 1 in 17 men aged 55 to 64 years and less than 1 in 25 men aged 35 to 54 years.

Furthermore, a rise was observed among young people (aged 18-24) regarding screening for prostate cancer; however, this can be attributed towards early detection programs conducted through PSA testing which has resultedantly increased awareness about early diagnosis among this demographic group as well as others at high risk of developing aggressive forms of the disease.

Regional Analysis:

North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced diagnostic technologies, and rising incidence rates of prostate cancer. In addition, government initiatives and funding programs are also responsible for its large share. For instance, as per a recent study by National Cancer Institute (NCI), from 2009 to 2011, NCI invested around USD X million in Prostate Cancer Biomarkers Research Consortium (PCBRC).

Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to increasing prevalence rates coupled with growing awareness about early diagnosis leading towards better treatment options. Moreover, economic development in this region has resulted in an increase in healthcare spending by local populace which is further fueling growth over next eight years.

Growth Factors:

  • Increasing incidence of prostate cancer
  • Growing awareness about prostate cancer and its early detection methods
  • Rising demand for minimally invasive diagnostic procedures
  • Technological advancements in prostate cancer diagnostics
  • Growing number of collaborations and partnerships between diagnostic companies and research institutes

Scope Of The Report

Report Attributes

Report Details

Report Title

Prostate Cancer Diagnostics Market Research Report

By Type

Tumor Biomarker Tests, Imaging, Biopsy, Other

By Application

age < 55, age 55-75, age > 75

By Companies

Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, BioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Prostate Cancer Diagnostics Market Report Segments:

The global Prostate Cancer Diagnostics market is segmented on the basis of:


Tumor Biomarker Tests, Imaging, Biopsy, Other

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


age < 55, age 55-75, age > 75

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Genomic Health
  2. Abbott
  3. OPKO
  4. Siemens Healthcare
  5. DiaSorin
  6. BioMeriux
  7. Roche
  8. MDx Health
  9. Beckman Coulter
  10. Myriad Genetics
  11. Ambry Genetics

Global Prostate Cancer Diagnostics Market Overview

Highlights of The Prostate Cancer Diagnostics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Tumor Biomarker Tests
    2. Imaging
    3. Biopsy
    4. Other
  1. By Application:

    1. age < 55
    2. age 55-75
    3. age > 75
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Prostate Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Prostate Cancer Diagnostics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Prostate cancer diagnostics is a term used to describe the various tests and procedures that are used to diagnose prostate cancer. These tests can include blood work, imaging scans, and biopsies.

Some of the major companies in the prostate cancer diagnostics market are Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, BioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics.

The prostate cancer diagnostics market is expected to register a CAGR of 7.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Prostate Cancer Diagnostics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Prostate Cancer Diagnostics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Prostate Cancer Diagnostics Market - Supply Chain
   4.5. Global Prostate Cancer Diagnostics Market Forecast
      4.5.1. Prostate Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Prostate Cancer Diagnostics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Prostate Cancer Diagnostics Market Absolute $ Opportunity

5. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      5.3.1. Tumor Biomarker Tests
      5.3.2. Imaging
      5.3.3. Biopsy
      5.3.4. Other
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      6.3.1. age < 55
      6.3.2. age 55-75
      6.3.3. age > 75
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029

9. North America Prostate Cancer Diagnostics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      9.4.1. age < 55
      9.4.2. age 55-75
      9.4.3. age > 75
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      9.7.1. Tumor Biomarker Tests
      9.7.2. Imaging
      9.7.3. Biopsy
      9.7.4. Other
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029

10. Latin America Prostate Cancer Diagnostics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      10.4.1. age < 55
      10.4.2. age 55-75
      10.4.3. age > 75
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      10.7.1. Tumor Biomarker Tests
      10.7.2. Imaging
      10.7.3. Biopsy
      10.7.4. Other
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029

11. Europe Prostate Cancer Diagnostics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      11.4.1. age < 55
      11.4.2. age 55-75
      11.4.3. age > 75
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      11.7.1. Tumor Biomarker Tests
      11.7.2. Imaging
      11.7.3. Biopsy
      11.7.4. Other
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Prostate Cancer Diagnostics Demand Share, 2019-2029

12. Asia Pacific Prostate Cancer Diagnostics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      12.4.1. age < 55
      12.4.2. age 55-75
      12.4.3. age > 75
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      12.7.1. Tumor Biomarker Tests
      12.7.2. Imaging
      12.7.3. Biopsy
      12.7.4. Other
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Prostate Cancer Diagnostics Demand Share, 2019-2029

13. Middle East & Africa Prostate Cancer Diagnostics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
      13.4.1. age < 55
      13.4.2. age 55-75
      13.4.3. age > 75
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
      13.7.1. Tumor Biomarker Tests
      13.7.2. Imaging
      13.7.3. Biopsy
      13.7.4. Other
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Prostate Cancer Diagnostics Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Prostate Cancer Diagnostics Market: Market Share Analysis
   14.2. Prostate Cancer Diagnostics Distributors and Customers
   14.3. Prostate Cancer Diagnostics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Genomic Health Overview Financials Developments Strategic Outlook
      14.4.2. Abbott Overview Financials Developments Strategic Outlook
      14.4.3. OPKO Overview Financials Developments Strategic Outlook
      14.4.4. Siemens Healthcare Overview Financials Developments Strategic Outlook
      14.4.5. DiaSorin Overview Financials Developments Strategic Outlook
      14.4.6. BioMeriux Overview Financials Developments Strategic Outlook
      14.4.7. Roche Overview Financials Developments Strategic Outlook
      14.4.8. MDx Health Overview Financials Developments Strategic Outlook
      14.4.9. Beckman Coulter Overview Financials Developments Strategic Outlook
      14.4.10. Myriad Genetics Overview Financials Developments Strategic Outlook
      14.4.11. Ambry Genetics Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us